Pharmx Technologies Limited, ANZ’s leading pharmacy ordering network, today announces a new multi-year strategic alliance with Sigma Healthcare Limited, one of Australia’s leading pharmaceutical wholesalers and retail pharmacy operators, further cementing Pharmx’s position in the industry’s supply chain.
The new alliance positions Pharmx as a core technology infrastructure partner to Sigma and the Chemist Warehouse network, supporting the digital framework of pharmacy supply chains across Australia, New Zealand and selected international markets. Sigma currently services over 3,500 pharmacy customers, including over 850 Chemist Warehouse, Amcal , and Discount Drug Stores franchises in Australia, and over 90 stores across the Republic of Ireland, the UAE, and New Zealand.
The alliance aims to improve the reliability, efficiency and transparency of ordering and supply-chain interactions. As part of the agreement, Pharmx becomes the preferred EDI (Electronic Data Interchange) service provider for Sigma wholesale and Chemist Warehouse retail operations across Australia and New Zealand.
The partnership goes beyond day-to-day ordering. The parties will aim to collaborate on global EDI capabilities and a range of other digital services designed to modernise pharmacy supply chains and support industry-wide efficiency and growth.
Summary of key terms
The strategic alliance initiatives will be delivered in two parts.
- Under Part A, Pharmx will become the preferred EDI partner for Sigma wholesale and Chemist Warehouse retail operations across Australia and New Zealand and will directly support growth plans in the New Zealand market. Sigma will renew its existing agreements for the provision of EDI services for its wholesale business for a further 5 years. Sigma will subscribe for approximately 59.95 million Pharmx shares (10% of Pharmx’s issued share capital) and will obtain a seat on the PharmxBoard, reinforcing the strategic alignment.
- Under Part B, Pharmx will expand the scope of services available to Sigma across additional international markets and new solution areas. Sigma will have the opportunity to subscribe for further Pharmx shares, up to an aggregate holding of 19.9% over the term of the alliance, with any such additional issues priced at the 30-day volume-weighted average price before the relevant issue and subject to Pharmx shareholder approval, to the extent required. Any new shares issued to Sigma under the alliance will be subject to a three-year escrow period.
In return for entering into the strategic alliance and the long-term commitment to procure services, Pharmx will pay Sigma an establishment fee of approximately $8.7 million.
Commenting on the strategic alliance, Pharmx CEO Tom Culver said:
“This strategic, multi-year partnership with Sigma reflects a shared commitment to strengthening important infrastructure that underpins the pharmacy sector, whilst looking to create efficiencies in supply and ordering. By simplifying connectivity across the supply chain, driving data led insights and delivering modern ordering solutions, we are aiming to improve the everyday lives of those managing pharmacies.”
“As an industry-first, independent platform, Pharmx continues to invest in the foundations that enable long-term, sustainable growth for the industry. We believe this partnership will help to deliver a simpler, more efficient, and cost-effective market, allowing pharmacies to reduce administrative burdens and giving them more time to spend focused on patient and community care.”
Sigma CEO Vikesh Ramsunder commented:
“We are pleased to formalise this long-term partnership with Pharmx. The progress of Pharmx’s product suite and the alignment of our growth objectives make this a compelling strategic fit. By investing in Pharmx, we move beyond a traditional supplier-customer relationship to a scalable partnership that reduces complexity, enhances supply chain performance, drives deeper analytics and creates value and growth opportunities for both organisations.”
The first part of the partnership between Pharmx and Sigma will start on 23 February 2026.
To see further details about the Pharmx and Sigma partnership, including the ASX announcement, please visit https://pharmx.com.au/investor-centre/
